Memorial Sloan Kettering Cancer Center

Akeso Enrolls First Patient in Global Phase III Gastric Cancer Trial

Hong Kong – September 28, 2026 -- Akeso, Inc. (9926.HK) has enrolled the first patient in COMPASSION-37, a global Phase III head-to-head trial testing its bispecific antibody cadonilimab against nivolumab as first-line treatment for HER2-negative advanced gastric and gastroesophageal junction (G/GEJ) adenocarcinoma.

Trial pits cadonilimab plus chemotherapy against nivolumab-based standard of care

The multicenter study compares cadonilimab combined with chemotherapy to chemotherapy with or without nivolumab in previously untreated, unresectable or metastatic G/GEJ patients. It is co-led by Dr. Yelena Y. Janjigian of Memorial Sloan Kettering Cancer Center, Professor Markus Möhler of Johannes Gutenberg University Mainz, and Professors Jiafu Ji and Lin Shen of Peking University Cancer Hospital. Janjigian, Möhler and Shen were investigators on the earlier CheckMate 649 trial, which established nivolumab plus chemotherapy as a global first-line standard.

NYU Langone Names Sean Berry Vice Chair of Radiation Oncology Physics

NYU Langone Names Sean Berry Vice Chair of Radiation Oncology Physics

New York – September 16, 2026 -- NYU Langone Health's Perlmutter Cancer Center has named Sean L. Berry, PhD, vice chair of physics and dosimetry in its Department of Radiation Oncology, recruiting a 20-year veteran of Memorial Sloan Kettering Cancer Center to lead treatment-planning quality and safety programs.

Berry moves from a regional physicist role overseeing multi-site radiation oncology operations

Before joining NYU Langone, Berry served as regional lead physicist and associate attending physicist at Memorial Sloan Kettering Cancer Center, managing clinical physics operations across outpatient sites in Westchester County, New York, and Bergen County, New Jersey. His duties included supervising faculty physicists, staff physicists and dosimetrists, regulatory readiness, accreditation activities, budget oversight, linear accelerator commissioning and standardizing radiation oncology practice across multiple locations.